Top 10 pharmaceutical companies by revenues | 2025 | iPharmaCenter

TOP PHARMACEUTICAL COMPANIES 2025

Rank	Company	Q1	H1	9M	Annual
1	Johnson & Johnson	$21.9
2	Roche	$18.7
3	Pfizer	$13.7
4	Merck	$13.6
5	AbbVie	$13.3
6	Novartis	$13.2
7	AstraZeneca	$12.9
8	Lilly	$12.7
9	BMS	$11.2
10	Sanofi	$11.2

1. JOHNSON AND JOHNSON

   Q1 REVENUES: In the first quarter of 2025, Johnson & Johnson reported revenues of $21.9 billion. The Innovative Medicine segment delivered good performance, achieving 4.2% year-over-year growth. This was primarily driven by continued strength in Oncology, led by Darzalex, Carvykti, Erleada, and Rybrevant; robust demand for Tremfya and Simponi in Immunology; and sustained momentum from Spravato in Neuroscience.

   
   

2. ROCHE

   Q1 REVENUES: In the first quarter of 2025, Roche reported revenues of $18.7 billion, reflecting 6% sales growth year-over-year. The Pharmaceuticals Division led performance with an 8% increase, driven by continued strong demand for key therapies. Ocrevus remained the top revenue contributor with $2.2 billion in sales, followed by Hemlibra at $1.4 billion and Vabysmo at $1.2 billion.

   
   

3. PFIZER

   Q1 REVENUES: Pfizer reported first-quarter 2025 revenues of $13.7 billion, representing a decline of $1.2 billion, or 8%, compared to the same period in the prior year. Despite the overall decrease, key products continued to perform strongly, with Eliquis generating $1.9 billion in revenue, the Prevnar family contributing $1.7 billion, and the Vyndaqel family reaching $1.5 billion.

   
   

4. MERCK

   Q1 REVENUES: In the first quarter of 2025, Merck reported pharmaceutical revenues of $13.6 billion. The decline was primarily driven by lower sales in vaccines, virology, and immunology. This was partially offset by continued growth in oncology, cardiology, and diabetes.

   Keytruda remained the company’s leading product with $7.2 billion in revenue, while Gardasil/Gardasil 9 contributed $1.3 billion.

   
   

5. ABBVIE

   Q1 REVENUES: AbbVie delivered first-quarter 2025 net revenues of $13.343 billion, reflecting an 8.4% increase on a reported basis. The company’s global immunology portfolio generated $6.264 billion in revenue, up 16.6% year-over-year. Growth was led by Skyrizi, which reported $3.4 billion in sales, and Rinvoq, which contributed $1.7 billion.

   
   

6. NOVARTIS

   
   

7. ASTRAZENECA

   
   

8. LILLY

   
   

9. BMS

   
   

10. SANOFI